Scholarlink

Purpose <p>To evaluate the survival outcomes of huge HCC (tumor size ≥ 10&#xa0;cm) after surgical resection (SR) with or without neoadjuvant hepatic arterial infusion chemotherapy (HAIC).</p> Patients and methods <p>119 huge HCC patients underwent SR in our Hospital (2010–2020). A new HAIC regimen (cisplatin, leucovorin, mitomycin-C and 5-FU infusion for 5 days plus 10&#xa0;ml lipiodol microvascular embolization) was adopted as the neoadjuvant therapy in 25 patients. Treatment responses were evaluated based on mRECIST criteria. The objective response rate (ORR), disease free survival (DFS), recurrence survival (RS) and overall survival (OS) were compared between the SR-only and neoadjuvant HAIC groups.</p> Results <p>Of the 119 patients, 65 patients were Vp2, 9 patients were Vp3 and 4 patients were Vp4. In the subgroup analysis, neoadjuvant HAIC group revealed significantly more severe clinical status. Of the neoadjuvant HAIC patients, ORR was 66.7%. Postoperative tumor recurrence was noted in 75% and 58.3% of the SR and neoadjuvant groups, of them 56.5% and 20.8% developed in ≤ 12 months. The median DFS, RS and OS in each group were 10 vs. 41 months (<i>p</i> = 0.016), 36 vs. 91 months and 46 vs. 96 months, respectively. Subgroup analysis revealed no significant survival difference of the RS in both patient groups with tumor recurrence ≤ 12 months (17 vs. 14 months) or &gt; 12 months/without recurrence (not reached vs. 113 months).</p> Conclusion <p>Our new regimen HAIC acted as an effective neoadjuvant therapy in reducing early recurrence rate and prolonged DFS of huge HCC after surgical resection.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Survival outcomes after surgical resection of huge HCC (≥ 10 cm) with or without neoadjuvant hepatic arterial infusion chemotherapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月23日

查看全文
  • Chia-Ling Chiang,
  • Yu-Chia Chen,
  • Huei-Lung Liang,
  • Cheng-Chung Tsai,
  • I-Shu Chen,
  • Gu-Sheng Yan,
  • Wei-Lun Tsai

摘要

Purpose

To evaluate the survival outcomes of huge HCC (tumor size ≥ 10 cm) after surgical resection (SR) with or without neoadjuvant hepatic arterial infusion chemotherapy (HAIC).

Patients and methods

119 huge HCC patients underwent SR in our Hospital (2010–2020). A new HAIC regimen (cisplatin, leucovorin, mitomycin-C and 5-FU infusion for 5 days plus 10 ml lipiodol microvascular embolization) was adopted as the neoadjuvant therapy in 25 patients. Treatment responses were evaluated based on mRECIST criteria. The objective response rate (ORR), disease free survival (DFS), recurrence survival (RS) and overall survival (OS) were compared between the SR-only and neoadjuvant HAIC groups.

Results

Of the 119 patients, 65 patients were Vp2, 9 patients were Vp3 and 4 patients were Vp4. In the subgroup analysis, neoadjuvant HAIC group revealed significantly more severe clinical status. Of the neoadjuvant HAIC patients, ORR was 66.7%. Postoperative tumor recurrence was noted in 75% and 58.3% of the SR and neoadjuvant groups, of them 56.5% and 20.8% developed in ≤ 12 months. The median DFS, RS and OS in each group were 10 vs. 41 months (p = 0.016), 36 vs. 91 months and 46 vs. 96 months, respectively. Subgroup analysis revealed no significant survival difference of the RS in both patient groups with tumor recurrence ≤ 12 months (17 vs. 14 months) or > 12 months/without recurrence (not reached vs. 113 months).

Conclusion

Our new regimen HAIC acted as an effective neoadjuvant therapy in reducing early recurrence rate and prolonged DFS of huge HCC after surgical resection.